We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    defenage
Previous Study | Return to List | Next Study

Clinical Evaluation of Day and Night Skin Care Creams Supplemented With MediCell Technology (MCT)'s Composition of Defensins and Supportive Molecules

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02765763
First Posted: May 9, 2016
Last Update Posted: February 1, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Advanced Dermatology
  Purpose
This is a placebo-controlled blinded clinical evaluation of day and night skin care creams supplemented by Medicell Technology's composition of defensins and supportive molecules determine the skin hydration and anti-aging properties of the topical test articles after repeated application to the skin of human subjects.

Condition Intervention Phase
Skin Aging Photoaging of Skin Drug: 2-Minute Reveal Masque Drug: 24/7 Barrier Repair Cream Drug: 8-in-1 BioSerum Drug: Null Formula 2-Minute Reveal Masque Drug: Null Formula 24/7 Barrier Repair Cream Drug: Null Formula 8-in-1 BioSerum Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Clinical Evaluation of Day and Night Skin Care Creams Supplemented With MediCell Technology (MCT)'s Composition of Defensins and Supportive Molecules

Further study details as provided by Advanced Dermatology:

Primary Outcome Measures:
  • Skin Evaluation assessing change from baseline to 12 weeks using Scale from 0 to 4 for pore size [ Time Frame: Baseline and 12 weeks ]
  • Skin Evaluation assessing change from baseline to 12 weeks using Scale from 0 to 4 for superficial wrinkles [ Time Frame: Baseline and 12 weeks ]
  • Skin Evaluation assessing change from baseline to 12 weeks using Scale from 0 to 4 for deep wrinkles [ Time Frame: Baseline and 12 weeks ]
  • Skin Evaluation assessing change from baseline to 12 weeks using Scale from 0 to 4 for skin radiancy [ Time Frame: Baseline and 12 weeks ]
  • Skin Evaluation assessing change from baseline to 12 weeks using Scale from 0 to 4 for skin turgor [ Time Frame: Baseline and 12 weeks ]
  • Skin Evaluation assessing change from baseline to 12 weeks using Scale from 0 to 4 for hyperpigmentation [ Time Frame: Baseline and 12 weeks ]
  • Skin Evaluation assessing change from baseline to 12 weeks using Scale from 0 to 4 for hypopigmentation [ Time Frame: Baseline and 12 weeks ]
  • Skin Evaluation assessing change from baseline to 12 weeks using Scale from 0 to 4 for erythema [ Time Frame: Baseline and 12 weeks ]
  • Skin Evaluation assessing change from baseline to 12 weeks using Scale from 0 to 4 for edema [ Time Frame: Baseline and 12 weeks ]
  • Skin Evaluation assessing change from baseline to 12 weeks using Scale from 0 to 4 for scaling and dryness [ Time Frame: Baseline and 12 weeks ]

Estimated Enrollment: 45
Actual Study Start Date: May 2016
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Sham Comparator: Group 1 Sham
Null Formula of the Test System
Drug: Null Formula 2-Minute Reveal Masque Drug: Null Formula 24/7 Barrier Repair Cream Drug: Null Formula 8-in-1 BioSerum
Active Comparator: Group 2 Treated
Full Formulas of Test System
Drug: 2-Minute Reveal Masque Drug: 24/7 Barrier Repair Cream Drug: 8-in-1 BioSerum

Detailed Description:

45 participants will be selected to participate in a placebo-controlled blinded trial comparing the use of the Full Formulas versus the Null Formulas (2 groups). 15 participants will be enrolled at each study site.

Each participant will test the Test System simultaneously as instructed: The Mask one-to-two times a week plus the Cream and the Serum twice daily (morning and evening); the detailed Directions are shown in Exhibit 2. The test System will be applied directly on face, postauricular and neck skin.

All study subjects will also be provided with Skinfo Clean But Not Dry cleanser and EltaMD UV Pure Broad Spectrum Sun Protective Factor (SPF) 47. Subjects will be instructed to wash their face twice daily with the cleanser and apply the sunscreen each morning after application of the Test System.

Both the study subjects and their physicians will be blinded in terms of the treatment group (the Full Formula or the Null Formula).

Subjects will be screening, consented and enrolled according to Good Clinical Practice.

There will be a 1-week washout of any skin care products deemed to be anti-aging. These products would include any using (as a main ingredient) antioxidants, retinol or retinoid, alpha hydroxyl acid, peptides, growth factors. Any other products that are to continue to be used must have been stable for the last 3 months and must be stable for the 12 weeks of the study.

Before beginning treatment, all participants will undergo medical imaging using the VISIA CA, QuantifiCare imaging system or similar non-invasive visual system. Additionally, their skin will be assessed for transepidermal water loss, wrinkle depth and elasticity (non invasive procedures). Optionally, skin will be tested using non-invasive methods for skin color, hydration, sebum content and will be evaluated using ultrasound scanner (DeremaLab Combo or similar).

Skin evaluation will be also performed at baseline, 6 weeks and 12 weeks using the Griffiths scale (2) as well as the skin evaluation scales for pores, superficial wrinkles, deep or muscle induced wrinkles, and skin radiancy, skin turgor, hyperpigmentation, hypopigmentation, erythema and edema in Blinded Evaluator Skin Assessment (Exhibit 3). The evaluation will be performed in person by the blinded investigators.

Subjects will complete a Consumer Questionnaire (Exhibit 4) at baseline, 6 week and 12 week visits.

Weekly phone calls will be made or emails will be sent (+/- 1 week window) to remind subjects to fill out compliance log, use mask, emphasize cream is applied before the serum. Follow-up appointments reminders will also be sent at this time.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Sex: Female
  • Fitzpatrick Skin Types: I-VI
  • Age: 40 - 75 years
  • Individuals who will be able to read, understand and give an informed consent relation to the study they are participating in.
  • Individuals who will be free of any dermatological or systemic disorder, which in the Principal Investigator's opinion, could interfere with the study results.
  • Individuals who will be in general good health and who will complete a preliminary medical history form mandated by the clinic.
  • Individuals who will be able to and agree to cooperate with the Investigator and research staff.
  • Individuals who will agree to have test products applied in accordance with the protocol and are able to complete the full course of the study.
  • Individuals who will agree to have 2 biopsies on the postauricular area if randomly selected.
  • Individuals who will agree to not participate in any other study during the entire length of the study and have not participated in a similar study in the past 30 days.

Exclusion Criteria:

  • Individuals who are currently taking any medications (topical or systemic) that may mask or interfere with the test results.
  • Individuals who have a history of any acute or chronic disease that might interfere with or increase the risk on study participation. (e.g., systemic lupus erythematosus, rheumatoid arthritis, HIV positive).
  • Individuals who are diagnosed with chronic skin allergies (atopic dermatitis/eczema) or recently treated skin cancer within the last 12 months.
  • Individuals who control their diabetes using insulin.
  • Individuals with any history, which in the Investigator's opinion, indicates the potential for harm to the subject or places the validity of the study in jeopardy.
  • Individuals who indicate that they are pregnant or are planning to become pregnant or nursing.
  • Individuals who have undergone any of the following procedures:

    • Botox within 6 months before enrollment into study and until study completion
    • Injectable filler within 3 months before enrollment into study and until study completion
    • Lasers or tissue tightening devices (ultherapy, radiofrequency, skin tightening, microcurrent or photorejuvenation, photodynamic therapy) within 6 months before enrollment into study and until study completion
    • Sculptra or Bellafill prior to enrollment into the study and until study completion
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02765763


Locations
United States, Illinois
Advanced Dermatology, LLC
Lincolnshire, Illinois, United States, 60069
Sponsors and Collaborators
Advanced Dermatology
Investigators
Principal Investigator: Amy F Taub, MD Advanced Dermatology. LLC
  More Information

Responsible Party: Advanced Dermatology
ClinicalTrials.gov Identifier: NCT02765763     History of Changes
Other Study ID Numbers: AFT Defenage
First Submitted: April 11, 2016
First Posted: May 9, 2016
Last Update Posted: February 1, 2017
Last Verified: June 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Defensins
Anti-Infective Agents